Patents by Inventor Soeren Snitker

Soeren Snitker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLP-1 COMPOSITIONS AND USES THEREOF
    Publication number: 20230093542
    Abstract: The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.1% (w/w) phenol and above 6.4 mg/ml sodium chloride, their preparation, kits comprising such compositions as well as uses thereof.
    Type: Application
    Filed: February 17, 2021
    Publication date: March 23, 2023
    Inventors: Dorthe Kot Engelund, Soeren Snitker, Andrew Mark Louw
  • GLP-1 compositions and uses thereof
    Patent number: 11318191
    Abstract: The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.1% (w/w) phenol and above 6.4 mg/ml sodium chloride, their preparation, kits comprising such compositions as well as uses thereof.
    Type: Grant
    Filed: February 17, 2021
    Date of Patent: May 3, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Dorthe Kot Engelund, Soeren Snitker, Andrew Mark Louw
  • GLP-1 COMPOSITIONS AND USES THEREOF
    Publication number: 20210252111
    Abstract: The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.1% (w/w) phenol and above 6.4 mg/ml sodium chloride, their preparation, kits comprising such compositions as well as uses thereof.
    Type: Application
    Filed: February 17, 2021
    Publication date: August 19, 2021
    Inventors: Dorthe Kot Engelund, Soeren Snitker, Andrew Mark Louw